Clinical Trial Update: A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating rituximab alone and in combination with Roferon-A (interferon alfa) in follicular and other CD20+ indolent lymphomas; completed with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Indolent Non-hodgkin Lymphoma

Drugs mentioned

• Rituxan (rituximab)
• Roferon-A (interferon alfa-2a)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Lymphoma | Phase 3 | Status: COMPLETED | Results posted: 2014-06-25